IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roudy who started this subject	10/15/2000 11:55:25 AM
From: Richard Belanger	Read Replies (1) of 1762

A good review of the state-of-the-art for treatment of NHL can be found at: medscape.com Lots of discussion of MAb treatments (rituximab, Zevalin and Bexxar) as well as prospects for combining MAbs with chemotherapy. The conclusion bodes well for Idec and patients: "There is a sense in the clinical community that the management of low-grade lymphomas is changing rapidly. For the optimists among us, it seems that a growing number of treatment strategies are producing the CR rates of 80% or more that Dr. Rai indicated would be necessary before real meaningful improvement in survival can be achieved. Dare we hope that in the coming decade, low-grade lymphomas may be immunologically cured?" Rich

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next